Intersect ENT, Inc.: management transactions · United States · SEC (Form 4)

About Intersect ENT, Inc.

Intersect ENT, Inc. was a United States medical technology company focused on ear, nose, and throat (ENT) care and formerly listed on the NASDAQ market in the United States. Founded in 2003, the company was headquartered in Menlo Park, California, in the heart of Silicon Valley. Its strategic niche was straightforward: to improve outcomes for patients with chronic sinus disease through localized drug-delivery devices and related ENT solutions used by surgeons. The company’s core business centered on steroid-eluting implants and sinus-treatment technologies. Its best-known products included PROPEL and SINUVA, two FDA-cleared implant platforms designed to deliver medication locally in connection with ENT procedures. Intersect ENT also broadened its portfolio through the October 2020 acquisition of Fiagon AG Medical Technologies, which added electromagnetic surgical navigation capabilities and complementary ENT offerings such as the VENSURE sinus dilation balloon and CUBE navigation system. This acquisition strengthened the company’s product breadth and helped extend its geographic reach beyond its original U.S.-centric footprint. From a competitive standpoint, Intersect ENT operated in a specialized but attractive segment of medtech. The company differentiated itself through a focused ENT franchise, a localized drug-delivery approach, and devices designed to complement rather than replace surgical treatment. Its competitive positioning was supported by the underlying demand for less invasive, more targeted therapies in chronic rhinosinusitis. While the business was primarily anchored in the United States, the Fiagon acquisition added a more international dimension and expanded its commercial and clinical reach. A major recent milestone was Medtronic’s announcement in August 2021 that it would acquire Intersect ENT, followed by completion of the transaction in May 2022. As a result, Intersect ENT is no longer an independent publicly traded company today. That said, the company remains relevant for investors monitoring historical SEC filings, including Form 4 insider transaction disclosures filed before the acquisition. For French-speaking investors, Intersect ENT represents a classic medtech niche player: focused, clinically differentiated, and ultimately absorbed into a larger global platform after building a recognized position in ENT care on the NASDAQ in the United States.